Latest Psoriatic arthritis Stories
MOUNTAIN VIEW, Calif., Oct. 25, 2012 /PRNewswire/ -- Tumor necrosis factor (TNF) inhibitors are currently the only therapeutic class available to psoriatic arthritis (PsA) patients in need of additional therapy beyond standard of care. This represents a significant unmet need for alternative therapies for TNF inhibitor refractory patients. New analysis from Frost & Sullivan's (http://www.healthcare.frost.com) United States Market for Psoriatic Arthritis Pharmacotherapy research...
MOUNTAIN VIEW, Calif., Oct. 18, 2012 /PRNewswire/ -- The availability of tumor necrosis factor (TNF) inhibitors has greatly improved the pharmacological management of rheumatoid arthritis (RA). Both patients and physicians are familiar with TNF inhibitors due to their long history; however, their many limitations such as high cost, potential side effects, and injection requirement have created a need for alternative therapies. This need, along with a potentially large patient...
Educational Conference on October 20 in Long Beach, California, Helps Young Adults with Arthritis, the Leading Cause of Disability in the United States LOS ANGELES, Oct 12, 2012 /PRNewswire-USNewswire/ -- The Arthritis Foundation is sponsoring the 3(rd) Annual PrimeTime symposium (formerly Arthritis in PrimeTime) on Saturday, October 20 at the Long Beach Renaissance Hotel in Long Beach, California. This premier educational and motivational event fosters active, productive and...
ATLANTA, Oct. 11, 2012 /PRNewswire/ -- More Americans are walking, according to a new report from the Centers for Disease Control and Prevention (CDC). While the news is a step in the right direction, the report also highlights a need for many more Americans to join the movement. The Arthritis Foundation is joining a global effort on Oct. 12, World Arthritis Day, to encourage physical activity among people with arthritis. To view the multimedia assets associated with this release,...
VANCOUVER, Oct. 9, 2012 /PRNewswire/ - Augurex Life Sciences Corp. today announced that it has formed an exclusive license agreement with Quest Diagnostics, for the development of a clinical laboratory-developed testing service for the U.S. market, based on Augurex's rheumatoid arthritis (RA) 14-3-3h biomarker. Quest Diagnostics is the world's leading diagnostic testing company, and serves approximately half of the physicians and hospitals in the United States. Quest Diagnostics...
Be Joint Smart educates public about devastating disease affecting 27,000 Oregonians PORTLAND, Ore., Oct. 9, 2012 /PRNewswire-USNewswire/ -- For the first-time ever, the Portland-based National Psoriasis Foundation and the Arthritis Foundation will partner to educate Americans about psoriatic arthritis, a chronic autoimmune disease that affects roughly 27,000 Oregonians. To emphasis the importance of early diagnosis and treatment, the Psoriasis Foundation and Arthritis Foundation...
Psoriasis Free for Life by Katy Wilson now available as a holistic treatment for Psoriasis. More information can be found at http://bestguidesreviews.com/psoriasis-free-for-life/. (PRWEB) October 08, 2012 Psoriasis is a common auto-immune disease that affects about 2% to 3% of the world's population. The cause of this disease remains a mystery and it has been noted that about 10 - 30% of all Psoriasis sufferers also have psoriatic arthritis (Source: en.wikipedia.org/wiki/Psoriasis)....
HORSHAM, Pa., Sept. 18, 2012 /PRNewswire/ -- Janssen Biotech, Inc. announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval of an investigational intravenous formulation of the anti-tumor necrosis factor (TNF)-alpha SIMPONI(®) (golimumab) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). An estimated 1.5 million Americans are living with RA,[1] a chronic...
Head of the Department of Dermatology and Allergology at the Academic Teaching Hospital Dresden-Friedrichstadt to direct Psoriasis journal. (PRWEB) September 07, 2012 Dr. Uwe Wollina has been named Editor-in-Chief of Dove Medical Press journal entitled Psoriasis: Targets and Therapy. Dr. Wollina added: “During the last decade a never expected and still growing interst in psoriasis and psoriatic arthritis has been noted. The development has been driven by basic reasearch in inflammation...
ANAHEIM, Calif., June 14, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced key elements of the Company's initial commercialization plans for H.P. Acthar® Gel (repository corticotropin injection) in the treatment of rheumatology-related indications already included on the FDA-approved package insert for Acthar. Acthar is indicated for multiple FDA-approved rheumatology-related conditions, including its use as adjunctive therapy in psoriatic...
